BTIG on Moonlake Immunotherapeutics (MLTX): 40 week data from VELA-1/2 'support new treatment standard'
Tweet Send to a Friend
BTIG analyst Julian Harrison reiterated a Buy rating and $30.00 price target on Moonlake Immunotherapeutics (NASDAQ: MLTX)The analyst commented, "40wk ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
